Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
06 déc. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
30 nov. 2023 16h48 HE
|
Biora Therapeutics, Inc.
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
13 nov. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: ...
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
09 nov. 2023 07h35 HE
|
ZyVersa Therapeutics
NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.
Organovo Highlights FXR314 Combination Therapy Potential and Plan
08 nov. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Asia-Pacific Anti-inflammatory Therapeutics Market to Reach $40.5 Billion by 2032 With CAGR of 5.4%: Says Allied Market Research
05 nov. 2023 18h55 HE
|
Allied Market Research
Wilmington, Delaware, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Asia-Pacific Anti-inflammatory Therapeutics Market, By Drug Class (Biologics, NSAIDs,...
Biora Therapeutics Submits Updated IND Application for BT-600
30 oct. 2023 16h05 HE
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Inflammatory Bowel Disease Treatment Market to hit USD 39.19 Billion by 2030 | Fortune Business Insights
30 oct. 2023 07h14 HE
|
Fortune Business Insights
Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The inflammatory bowel disease treatment market revenue is set to rise from USD 26.55 billion in 2023 to USD 39.19 billion by 2030 at a CAGR of 5.7%...
Inflammatory Bowel Disease Treatment Market Size to Surpass USD 37.00 Billion by 2029, exhibiting a CAGR of 5.7%
05 oct. 2023 04h35 HE
|
Fortune Business Insights
Pune, India, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The inflammatory bowel disease treatment market size was valued at USD 23.90 billion in 2021 and projected to grow USD 37.00 billion by 2029,...
Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities
20 sept. 2023 04h43 HE
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...